Velnacrine maleate improves delayed matching performance by aged monkeys

W. J. Jackson, J. J. Buccafusco, Alvin V Terry, D. J. Turk, D. K. Rush

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Velnacrine maleate is a novel, orally active acetylcholinesterase inhibitor of the acridine class with a longer duration of action than physostigmine. Velnacrine has shown efficacy in the treatment of Alzheimer's disease and in improving both normal and experimentally impaired mnemonic function in animals and humans. To characterize this action further, the present study evaluated velnacrine for its ability to ameliorate the decline in short-term memory associated with aging in non-human primates at two time points after velnacrine administration: (1) 30 min and (2) 24 h. Initially, doses of 1, 2, 4, and 6 mg/kg, PO (free base corrected) were administered once to each of six aged (25-40 years), memory-impaired macaques that had been trained to perform a delayed matching-to-sample (DMTS) paradigm. The dose associated with the greatest improvement in session performance was administered three more times to the same individual. Four of the six monkeys showed improved DMTS performance during the repeated best dose phase (phase 2). Almost all of the improvement occurred during long-delay trials. Compared to placebo trials, velnacrine induced a significant improvement of long delay DMTS (58.0-66.7%, 13.4% of the placebo value). Long delay DMTS remained significantly improved during the test session conducted 24 h following velnacrine administration. Pharmacokinetic analysis following administration of 4 or 6 mg/kg velnacrine to three aged monkeys revealed peak plasma concentrations ranging from 27 to 166 ng/ml, 30-60 min after dosing. Six hours after dosing velnacrine plasma levels decreased to 5.1-11.8 ng/ml; and 24 h after dosing, velnacrine plasma levels were less than the limit of quantitation (5 ng/ml). Thus, the improved DMTS performance observed 0.5-1.5 h after velnacrine administration coincided with the peak absorption of the drug in plasma; however, the improved DMTS performance observed 24 h post-dosing was not explained by plasma levels. Possibly, the 24-h improvement was induced by some secondary process, such as long term potentiation.

Original languageEnglish (US)
Pages (from-to)391-398
Number of pages8
JournalPsychopharmacology
Volume119
Issue number4
DOIs
StatePublished - Jun 1 1995

Fingerprint

Haplorhini
Placebos
velnacrine
Acridines
Physostigmine
Aptitude
Long-Term Potentiation
Cholinesterase Inhibitors
Macaca
Short-Term Memory
Primates
Alzheimer Disease
Pharmacokinetics
Pharmaceutical Preparations

Keywords

  • Acetylcholinesterase
  • Aging
  • Delayed response
  • Memory
  • Non-human primates

ASJC Scopus subject areas

  • Pharmacology

Cite this

Velnacrine maleate improves delayed matching performance by aged monkeys. / Jackson, W. J.; Buccafusco, J. J.; Terry, Alvin V; Turk, D. J.; Rush, D. K.

In: Psychopharmacology, Vol. 119, No. 4, 01.06.1995, p. 391-398.

Research output: Contribution to journalArticle

Jackson, WJ, Buccafusco, JJ, Terry, AV, Turk, DJ & Rush, DK 1995, 'Velnacrine maleate improves delayed matching performance by aged monkeys', Psychopharmacology, vol. 119, no. 4, pp. 391-398. https://doi.org/10.1007/BF02245854
Jackson, W. J. ; Buccafusco, J. J. ; Terry, Alvin V ; Turk, D. J. ; Rush, D. K. / Velnacrine maleate improves delayed matching performance by aged monkeys. In: Psychopharmacology. 1995 ; Vol. 119, No. 4. pp. 391-398.
@article{503cd6a5cdb24eaca3f8fd3f76af4c78,
title = "Velnacrine maleate improves delayed matching performance by aged monkeys",
abstract = "Velnacrine maleate is a novel, orally active acetylcholinesterase inhibitor of the acridine class with a longer duration of action than physostigmine. Velnacrine has shown efficacy in the treatment of Alzheimer's disease and in improving both normal and experimentally impaired mnemonic function in animals and humans. To characterize this action further, the present study evaluated velnacrine for its ability to ameliorate the decline in short-term memory associated with aging in non-human primates at two time points after velnacrine administration: (1) 30 min and (2) 24 h. Initially, doses of 1, 2, 4, and 6 mg/kg, PO (free base corrected) were administered once to each of six aged (25-40 years), memory-impaired macaques that had been trained to perform a delayed matching-to-sample (DMTS) paradigm. The dose associated with the greatest improvement in session performance was administered three more times to the same individual. Four of the six monkeys showed improved DMTS performance during the repeated best dose phase (phase 2). Almost all of the improvement occurred during long-delay trials. Compared to placebo trials, velnacrine induced a significant improvement of long delay DMTS (58.0-66.7{\%}, 13.4{\%} of the placebo value). Long delay DMTS remained significantly improved during the test session conducted 24 h following velnacrine administration. Pharmacokinetic analysis following administration of 4 or 6 mg/kg velnacrine to three aged monkeys revealed peak plasma concentrations ranging from 27 to 166 ng/ml, 30-60 min after dosing. Six hours after dosing velnacrine plasma levels decreased to 5.1-11.8 ng/ml; and 24 h after dosing, velnacrine plasma levels were less than the limit of quantitation (5 ng/ml). Thus, the improved DMTS performance observed 0.5-1.5 h after velnacrine administration coincided with the peak absorption of the drug in plasma; however, the improved DMTS performance observed 24 h post-dosing was not explained by plasma levels. Possibly, the 24-h improvement was induced by some secondary process, such as long term potentiation.",
keywords = "Acetylcholinesterase, Aging, Delayed response, Memory, Non-human primates",
author = "Jackson, {W. J.} and Buccafusco, {J. J.} and Terry, {Alvin V} and Turk, {D. J.} and Rush, {D. K.}",
year = "1995",
month = "6",
day = "1",
doi = "10.1007/BF02245854",
language = "English (US)",
volume = "119",
pages = "391--398",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Velnacrine maleate improves delayed matching performance by aged monkeys

AU - Jackson, W. J.

AU - Buccafusco, J. J.

AU - Terry, Alvin V

AU - Turk, D. J.

AU - Rush, D. K.

PY - 1995/6/1

Y1 - 1995/6/1

N2 - Velnacrine maleate is a novel, orally active acetylcholinesterase inhibitor of the acridine class with a longer duration of action than physostigmine. Velnacrine has shown efficacy in the treatment of Alzheimer's disease and in improving both normal and experimentally impaired mnemonic function in animals and humans. To characterize this action further, the present study evaluated velnacrine for its ability to ameliorate the decline in short-term memory associated with aging in non-human primates at two time points after velnacrine administration: (1) 30 min and (2) 24 h. Initially, doses of 1, 2, 4, and 6 mg/kg, PO (free base corrected) were administered once to each of six aged (25-40 years), memory-impaired macaques that had been trained to perform a delayed matching-to-sample (DMTS) paradigm. The dose associated with the greatest improvement in session performance was administered three more times to the same individual. Four of the six monkeys showed improved DMTS performance during the repeated best dose phase (phase 2). Almost all of the improvement occurred during long-delay trials. Compared to placebo trials, velnacrine induced a significant improvement of long delay DMTS (58.0-66.7%, 13.4% of the placebo value). Long delay DMTS remained significantly improved during the test session conducted 24 h following velnacrine administration. Pharmacokinetic analysis following administration of 4 or 6 mg/kg velnacrine to three aged monkeys revealed peak plasma concentrations ranging from 27 to 166 ng/ml, 30-60 min after dosing. Six hours after dosing velnacrine plasma levels decreased to 5.1-11.8 ng/ml; and 24 h after dosing, velnacrine plasma levels were less than the limit of quantitation (5 ng/ml). Thus, the improved DMTS performance observed 0.5-1.5 h after velnacrine administration coincided with the peak absorption of the drug in plasma; however, the improved DMTS performance observed 24 h post-dosing was not explained by plasma levels. Possibly, the 24-h improvement was induced by some secondary process, such as long term potentiation.

AB - Velnacrine maleate is a novel, orally active acetylcholinesterase inhibitor of the acridine class with a longer duration of action than physostigmine. Velnacrine has shown efficacy in the treatment of Alzheimer's disease and in improving both normal and experimentally impaired mnemonic function in animals and humans. To characterize this action further, the present study evaluated velnacrine for its ability to ameliorate the decline in short-term memory associated with aging in non-human primates at two time points after velnacrine administration: (1) 30 min and (2) 24 h. Initially, doses of 1, 2, 4, and 6 mg/kg, PO (free base corrected) were administered once to each of six aged (25-40 years), memory-impaired macaques that had been trained to perform a delayed matching-to-sample (DMTS) paradigm. The dose associated with the greatest improvement in session performance was administered three more times to the same individual. Four of the six monkeys showed improved DMTS performance during the repeated best dose phase (phase 2). Almost all of the improvement occurred during long-delay trials. Compared to placebo trials, velnacrine induced a significant improvement of long delay DMTS (58.0-66.7%, 13.4% of the placebo value). Long delay DMTS remained significantly improved during the test session conducted 24 h following velnacrine administration. Pharmacokinetic analysis following administration of 4 or 6 mg/kg velnacrine to three aged monkeys revealed peak plasma concentrations ranging from 27 to 166 ng/ml, 30-60 min after dosing. Six hours after dosing velnacrine plasma levels decreased to 5.1-11.8 ng/ml; and 24 h after dosing, velnacrine plasma levels were less than the limit of quantitation (5 ng/ml). Thus, the improved DMTS performance observed 0.5-1.5 h after velnacrine administration coincided with the peak absorption of the drug in plasma; however, the improved DMTS performance observed 24 h post-dosing was not explained by plasma levels. Possibly, the 24-h improvement was induced by some secondary process, such as long term potentiation.

KW - Acetylcholinesterase

KW - Aging

KW - Delayed response

KW - Memory

KW - Non-human primates

UR - http://www.scopus.com/inward/record.url?scp=0029035590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029035590&partnerID=8YFLogxK

U2 - 10.1007/BF02245854

DO - 10.1007/BF02245854

M3 - Article

VL - 119

SP - 391

EP - 398

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -